Penumbra Inc
Penumbra, Inc. (NYSE: PEN) develops, manufactures and markets medical devices used to treat vascular conditions, including ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia and aneurysms. Its products support thrombectomy, embolization and vascular access procedures, and are sold primarily… From the company’s description.
Over the twelve months to Sep 30, 2026, Penumbra Inc reported revenue of $1.56B, up 17.0% from a year earlier, and net income of $157.02M. Its operating margin was 12.1%, and operations generated $261.05M in cash. In fiscal 2025, it reported revenue of $1.40B, up 17.5% from fiscal 2024, and net income of $177.69M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Penumbra Inc does
In the company’s own words
Penumbra, Inc. (NYSE: PEN) develops, manufactures and markets medical devices used to treat vascular conditions, including ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia and aneurysms. Its products support thrombectomy, embolization and vascular access procedures, and are sold primarily to hospitals and other healthcare providers for use by specialist physicians. Penumbra operates as one reportable segment and groups its products into thrombectomy and embolization and access categories; in 2025, these categories generated $947.9 million and $455.7 million in revenue, respectively. Its portfolio includes the Indigo System and Lightning technologies for thrombectomy, the Penumbra System for neurovascular clot removal, Ruby and Penumbra Coil products for embolization, Neuron and BENCHMARK access catheters, and the Artemis Neuro Evacuation Device. The company sells directly in the United States, most of Europe, Canada, Australia and Singapore, and uses distributors in select international markets. Revenue totaled $1.40 billion in 2025. Founded in 2004, Penumbra has developed products across thrombectomy, access, embolization and neurosurgical markets. Its website is www.penumbrainc.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- ALAMEDA, CA
- Fiscal year end
- December
- CIK
- 1321732
- SIC
- 3841
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Penumbra Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Penumbra Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Penumbra Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Penumbra Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Penumbra Inc's last four quarterly filings that the numbers alone won't show?”